168 related articles for article (PubMed ID: 26674097)
1. A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
Seibold P; Schmezer P; Behrens S; Michailidou K; Bolla MK; Wang Q; Flesch-Janys D; Nevanlinna H; Fagerholm R; Aittomäki K; Blomqvist C; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Lambrechts D; Wildiers H; Kristensen V; Alnæs GG; Nord S; Borresen-Dale AL; Hooning MJ; Hollestelle A; Jager A; Seynaeve C; Li J; Liu J; Humphreys K; Dunning AM; Rhenius V; Shah M; Kabisch M; Torres D; Ulmer HU; Hamann U; Schildkraut JM; Purrington KS; Couch FJ; Hall P; Pharoah P; Easton DF; Schmidt MK; Chang-Claude J; Popanda O
BMC Cancer; 2015 Dec; 15():978. PubMed ID: 26674097
[TBL] [Abstract][Full Text] [Related]
2. Germline variants of base excision repair genes and breast cancer: A polymorphism in DNA polymerase gamma modifies gene expression and breast cancer risk.
Popanda O; Seibold P; Nikolov I; Oakes CC; Burwinkel B; Hausmann S; Flesch-Janys D; Plass C; Chang-Claude J; Schmezer P
Int J Cancer; 2013 Jan; 132(1):55-62. PubMed ID: 22684821
[TBL] [Abstract][Full Text] [Related]
3. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy.
Lei J; Rudolph A; Moysich KB; Rafiq S; Behrens S; Goode EL; Pharoah PP; Seibold P; Fasching PA; Andrulis IL; Kristensen VN; Couch FJ; Hamann U; Hooning MJ; Nevanlinna H; Eilber U; Bolla MK; Dennis J; Wang Q; Lindblom A; Mannermaa A; Lambrechts D; García-Closas M; Hall P; Chenevix-Trench G; Shah M; Luben R; Haeberle L; Ekici AB; Beckmann MW; Knight JA; Glendon G; Tchatchou S; Alnæs GI; Borresen-Dale AL; Nord S; Olson JE; Hallberg E; Vachon C; Torres D; Ulmer HU; Rüdiger T; Jager A; van Deurzen CH; Tilanus-Linthorst MM; Muranen TA; Aittomäki K; Blomqvist C; Margolin S; Kosma VM; Hartikainen JM; Kataja V; Hatse S; Wildiers H; Smeets A; Figueroa J; Chanock SJ; Lissowska J; Li J; Humphreys K; Phillips KA; ; Linn S; Cornelissen S; van den Broek SA; Kang D; Choi JY; Park SK; Yoo KY; Hsiung CN; Wu PE; Hou MF; Shen CY; Teo SH; Taib NA; Yip CH; Ho GF; Matsuo K; Ito H; Iwata H; Tajima K; Dunning AM; Benitez J; Czene K; Sucheston LE; Maishman T; Tapper WJ; Eccles D; Easton DF; Schmidt MK; Chang-Claude J
Breast Cancer Res; 2015 Feb; 17(1):18. PubMed ID: 25849327
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
5. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
Anticancer Res; 2014 Jun; 34(6):3031-7. PubMed ID: 24922669
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients--potential differential effects by radiotherapy?
Seibold P; Hall P; Schoof N; Nevanlinna H; Heikkinen T; Benner A; Liu J; Schmezer P; Popanda O; Flesch-Janys D; Chang-Claude J
Breast; 2013 Oct; 22(5):817-23. PubMed ID: 23489758
[TBL] [Abstract][Full Text] [Related]
7. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.
Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I
Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366
[TBL] [Abstract][Full Text] [Related]
8. The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.
Fagerholm R; Schmidt MK; Khan S; Rafiq S; Tapper W; Aittomäki K; Greco D; Heikkinen T; Muranen TA; Fasching PA; Janni W; Weinshilboum R; Loehberg CR; Hopper JL; Southey MC; Keeman R; Lindblom A; Margolin S; Mannermaa A; Kataja V; Chenevix-Trench G; ; Lambrechts D; Wildiers H; Chang-Claude J; Seibold P; Couch FJ; Olson JE; Andrulis IL; Knight JA; García-Closas M; Figueroa J; Hooning MJ; Jager A; Shah M; Perkins BJ; Luben R; Hamann U; Kabisch M; Czene K; Hall P; Easton DF; Pharoah PD; Liu J; Eccles D; Blomqvist C; Nevanlinna H
Oncotarget; 2015 Apr; 6(10):7390-407. PubMed ID: 25823661
[TBL] [Abstract][Full Text] [Related]
9. The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S; Madden SF; Furney SJ; Fan Y; McCormack M; Stapleton C; Cremona M; Cavalleri GL; Milewska M; Elster N; Carr A; Fay J; Kay EW; Kennedy S; Crown J; Gallagher WM; Hennessy BT; Eustace AJ
Oncotarget; 2016 Nov; 7(46):75518-75525. PubMed ID: 27776352
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
Wu X; Ye Y; Rosell R; Amos CI; Stewart DJ; Hildebrandt MA; Roth JA; Minna JD; Gu J; Lin J; Buch SC; Nukui T; Ramirez Serrano JL; Taron M; Cassidy A; Lu C; Chang JY; Lippman SM; Hong WK; Spitz MR; Romkes M; Yang P
J Natl Cancer Inst; 2011 May; 103(10):817-25. PubMed ID: 21483023
[TBL] [Abstract][Full Text] [Related]
11. Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer.
Li S; Lang GT; Zhang YZ; Yu KD; Shao ZM; Zhang Q
Cancer Med; 2018 Sep; 7(9):4202-4207. PubMed ID: 30032483
[TBL] [Abstract][Full Text] [Related]
12. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer.
Shiraishi K; Kohno T; Tanai C; Goto Y; Kuchiba A; Yamamoto S; Tsuta K; Nokihara H; Yamamoto N; Sekine I; Ohe Y; Tamura T; Yokota J; Kunitoh H
J Clin Oncol; 2010 Nov; 28(33):4945-52. PubMed ID: 20940192
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
Wu X; Gu J; Wu TT; Swisher SG; Liao Z; Correa AM; Liu J; Etzel CJ; Amos CI; Huang M; Chiang SS; Milas L; Hittelman WN; Ajani JA
J Clin Oncol; 2006 Aug; 24(23):3789-98. PubMed ID: 16785472
[TBL] [Abstract][Full Text] [Related]
14. The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
Teo MT; Landi D; Taylor CF; Elliott F; Vaslin L; Cox DG; Hall J; Landi S; Bishop DT; Kiltie AE
Carcinogenesis; 2012 Mar; 33(3):581-6. PubMed ID: 22166496
[TBL] [Abstract][Full Text] [Related]
15. Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.
Larsen V; Barlow WE; Yang JJ; Zhu Q; Liu S; Kwan ML; Ergas IJ; Roh JM; Hutchins LF; Kadlubar SA; Albain KS; Rae JM; Yeh IT; Ravdin PM; Martino S; Lyss AP; Osborne CK; Hortobagyi GN; Kushi LH; Hayes DF; Ambrosone CB; Yao S
Clin Breast Cancer; 2019 Aug; 19(4):225-235.e2. PubMed ID: 30928413
[TBL] [Abstract][Full Text] [Related]
16. XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.
Ye S; Rong J; Huang SH; Zheng ZS; Yun M; Wang SM
Asian Pac J Cancer Prev; 2012; 13(10):4923-6. PubMed ID: 23244082
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Albain KS; Barlow WE; Shak S; Hortobagyi GN; Livingston RB; Yeh IT; Ravdin P; Bugarini R; Baehner FL; Davidson NE; Sledge GW; Winer EP; Hudis C; Ingle JN; Perez EA; Pritchard KI; Shepherd L; Gralow JR; Yoshizawa C; Allred DC; Osborne CK; Hayes DF;
Lancet Oncol; 2010 Jan; 11(1):55-65. PubMed ID: 20005174
[TBL] [Abstract][Full Text] [Related]
18. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
19. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
[TBL] [Abstract][Full Text] [Related]
20. The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer.
Söderlund Leifler K; Asklid A; Fornander T; Stenmark Askmalm M
J Cancer Res Clin Oncol; 2015 May; 141(5):797-804. PubMed ID: 25354554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
